Rituximab for eradicating inhibitors in people with acquired haemophilia A.

ABSTRACT:

Background

Acquired haemophilia A is a rare bleeding disorder caused by the development of specific autoantibodies against coagulation factor VIII. Standard treatment, usually steroids alone, or in combination with cyclophosphamide, aims to stop acute bleeds by using haemostatic agents to promote clotting. Rituximab may be an alternative approach to the treatment of acquired haemophilia by eradicating FVIII autoantibodies. This is an update of a previously published Cochrane Review.

Objectives

To assess the efficacy and adverse effects of rituximab for treating people with acquired haemophilia A.

Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's trials registers, comprising references identified from comprehensive electronic databas

SUBMITTER: Remmington T 

PROVIDER: S-EPMC8407509 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature